Health Trials

About this trial

Primary aldosteronism (PA) is a major cause of secondary hypertension, yet its optimal diagnosis and management remain challenging. This study comprehensively evaluates adrenal venous sampling (AVS), addressing key clinical, technical, and methodological issues, and aims to clarify the relationship between AVS-guided management and long-term clinical and biochemical outcomes to optimize patient care and prognosis.

Eligibility criteria

Qualifiers

Patients with confirmed primary aldosteronism;

Patients undergoing adrenal venous sampling for subtype classification of primary aldosteronism.

Disqualifiers

Severe comorbidity, including stroke, myocardial infarction, heart failure, severe valvular heart disease, liver cirrhosis, and metastatic tumor within the previous 3 months；

An estimated glomerular filtration rate <45 ml/min/1.73 m2, or serum creatinine >176 μmol/L；

Patients who refuse adrenalectomy;

Suspected of having an adrenocortical carcinoma;

Trial design

Treatments tested in this trial

  • adrenal venous sampling

Treatment groups

5,000 Participants
are divided into 1 treatment group

Locations

76
The first affiliated hospital of USTC230036, HefeiAnhui, China
Beijing Luhe Hospital, Capital Medical University101100, BeijingBeijing Municipality, China
China-Japan Friendship Hospital100029, BeijingBeijing Municipality, China
Chuiyangliu Hospital affiliated to Tsinghua University100022, BeijingBeijing Municipality, China

Sponsors and collaborators

Chinese Academy of Medical Sciences, Fuwai Hospital

Lead sponsor

Source ClinicalTrials.gov